GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $29.29 and traded as low as $28.77. GENMAB A/S/S shares last traded at $29.43, with a volume of 342,399 shares.
GENMAB A/S/S Stock Down 0.3 %
The business has a 50 day moving average price of $29.29 and a two-hundred day moving average price of $30.40.
GENMAB A/S/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
See Also
- Five stocks we like better than GENMAB A/S/S
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Silicon Motion Proves That AI in Motion Stays in Motion
- 3 Healthcare Dividend Stocks to Buy
- Undervalued UnitedHealth Group Won’t Be For Long
- What is a SEC Filing?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
